—Even long after the active phase of thyroid eye disease has subsided, a multitude of challenging quality-of-life issues may persist. Several recent studies have established that the physical ...

The most useful biomarker for extraocular muscle enlargement in thyroid eye disease (TED) is unclear. According to this study, higher thyroid-stimulating antibody (TSAb) levels and older age were ...

Q: Lately, we've been seeing a lot of ads on TV for a medication to treat thyroid eye disease. My daughter, who is 23, suffers from dry eyes, and now she's sure she has it. What is thyroid eye disease ...

The FDA granted priority review to veligrotug for the treatment of thyroid eye disease, according to a press release from ...

Artificial intelligence (AI) can help diagnose thyroid eye disease and assess its severity by analyzing CT scans, research shows. The technology could automate screening and help ensure patients who ...

As mentioned in Overview, most thyroid eye disease (TED) cases are closely related to hyperthyroidism. Approximately 85% of patients with TED develop the disease around 18 months before or after the ...

A collaborative program designed to treat thyroid eye disease (TED) at the University of Utah offers patients access to highly customized treatments—including a delicate endoscopic surgery at the John ...

(Reuters) -Viridian Therapeutics said on Tuesday its experimental treatment helped significantly reduce symptoms of thyroid eye disease (TED) in a late-stage study, setting the stage to become the ...

Annie Larsson, 40, is no stranger to chronic conditions. She was diagnosed with type 1 diabetes at a young age and had it “completely managed” for years. Then, right before the Covid pandemic began, ...

Nearly 2 years after their final infusion with the IGF-IR inhibitor teprotumumab (Tepezza), 82% of patients with thyroid eye disease did not need further treatment for their symptoms, revealed ...

BOSTON—Most patients with thyroid eye disease treated with teprotumumab didn’t require additional treatments nearly 2 years later, according to industry-supported research being presented Sunday at ...

Argenx SE shares fell the most in seven months after the biotech firm said it will discontinue late-stage trials for an experimental medicine to treat an autoimmune disease affecting the eyes.